Kenvue (NYSE:KVUE) Given New $21.00 Price Target at Citigroup

Kenvue (NYSE:KVUE) had its price target lowered by Citigroup from $25.00 to $21.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

KVUE has been the subject of a number of other research reports. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays raised shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus price target of $23.18.

Kenvue Trading Down 1.0 %

Shares of KVUE stock opened at $20.83 on Wednesday. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a market cap of $39.94 billion, a price-to-earnings ratio of 37.87, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a fifty day moving average of $22.50 and a 200-day moving average of $21.64.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.31 EPS. On average, equities research analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Leo Wealth LLC boosted its stake in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the last quarter. Alerus Financial NA boosted its stake in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after acquiring an additional 492 shares during the last quarter. Wolff Wiese Magana LLC boosted its stake in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the last quarter. Finally, Marathon Capital Management boosted its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after acquiring an additional 514 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.